| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 24.09. | FDA knocks back Biogen's high-dose Spinraza | ||
| 24.09. | Lilly names Houston as site for $6.5bn API facility | ||
| 23.09. | Manufacturing issues block FDA nod for Scholar Rock SMA drug | ||
| 23.09. | Roche's oral SERD comes good in 2nd-line breast cancer trial | ||
| 23.09. | Angelini taps Sovargen for epilepsy drug in $550m deal | ||
| 23.09. | BMS says it will set Cobenfy's UK price the same as the US | ||
| 23.09. | Alarm as Trump peddles unproven causes of autism | ||
| 22.09. | After internal setbacks, Pfizer buys obesity player Metsera | ||
| 22.09. | Bayer starts pivotal Parkinson's cell therapy trial | ||
| 22.09. | Stealth's patience rewarded as FDA approves Barth drug | ||
| 22.09. | FDA clears subcutaneous Keytruda in a boost to MSD | ||
| 19.09. | Breaking: ACIP pushes back vote on hepatitis B vaccine | ||
| 19.09. | Biogen buys CNS delivery specialist Alcyone Therapeutics | ||
| 19.09. | Closed Loop Medicine launches digital GLP-1 dosing platform | ||
| 19.09. | Lila Sciences' $235m first round, and other biofinancings | ||
| 19.09. | UK specialists call for more testing on psychedelics | ||
| 19.09. | ACIP votes against first-dose MMRV for under 4s | ||
| 18.09. | Regeneron drug on track to be second FOP treatment | ||
| 18.09. | electronRx cues up launch of digital respiratory platform | ||
| 18.09. | Oral GLP-1 contest ramps up with new Novo Nordisk data | ||
| 18.09. | Roche poised to buy MASH drug developer 89bio for $3.5bn | ||
| 17.09. | Monarez: Kennedy has plan to change child vaccine schedule | ||
| 17.09. | Lilly weakens on data reveal for oral obesity candidate | ||
| 17.09. | PHTI delivers its verdict on DHTs for opioid use disorder | ||
| 17.09. | As Trump visits UK, GSK pledges $30bn in US investment |